METLIPTIN 50:500MG Tablet Price in Pakistan

View latest Price, manufacturer, formulation, and pack details of METLIPTIN 50:500MG Tablet.

Available Products of METLIPTIN 50:500MG Tablet

METLIPTIN 50:500MG Tablet 28's

Reg#: 082132

Description of METLIPTIN 50:500MG Tablet

Vildagliptin 50mg + Metformin Hcl 500mg

Medicine Info

Pack Size: 28's

Company: Tabros Pharma (Pvt) Ltd.

Price of METLIPTIN 50:500MG Tablet

Price: Rs. 2604.40

Related Keywords

  • METLIPTIN 50:500MG Tablet price in Pakistan
  • METLIPTIN 50:500MG Tablet tablet price
  • METLIPTIN 50:500MG Tablet Capsule price
  • Tabros Pharma (Pvt) Ltd. METLIPTIN 50:500MG Tablet price
  • Buy METLIPTIN 50:500MG Tablet online
  • METLIPTIN 50:500MG Tablet 50mg uses
  • METLIPTIN 50:500MG Tablet syrup price
  • METLIPTIN 50:500MG Tablet pack 28's cost

METLIPTIN 50:500MG Tablet 14's

Reg#: 082132

Description of METLIPTIN 50:500MG Tablet

Vildagliptin 50mg + Metformin Hcl 500mg

Medicine Info

Pack Size: 14's

Company: Tabros Pharma (Pvt) Ltd.

Price of METLIPTIN 50:500MG Tablet

Price: Rs. 1303.20

Related Keywords

  • METLIPTIN 50:500MG Tablet price in Pakistan
  • METLIPTIN 50:500MG Tablet tablet price
  • METLIPTIN 50:500MG Tablet Capsule price
  • Tabros Pharma (Pvt) Ltd. METLIPTIN 50:500MG Tablet price
  • Buy METLIPTIN 50:500MG Tablet online
  • METLIPTIN 50:500MG Tablet 50mg uses
  • METLIPTIN 50:500MG Tablet syrup price
  • METLIPTIN 50:500MG Tablet pack 14's cost

Alternatives brands of METLIPTIN 50:500MG Tablet

Explore alternative brands for METLIPTIN 50:500MG Tablet below.

View Alternatives

Explore More Medicines

METLIPTIN 50:850MG Tablet

Tabros Pharma (Pvt) Ltd.

MRP: Rs. 983.7696

METLIPTIN 50:850MG Tablet

Tabros Pharma (Pvt) Ltd.

MRP: Rs. 1376.5488

METLIPTIN 50:1000MG Tablet

Tabros Pharma (Pvt) Ltd.

MRP: Rs. 3051.4968

METLIPTIN 50:1000MG Tablet

Tabros Pharma (Pvt) Ltd.

MRP: Rs. 1976.6208

METLIPTIN 50:1000MG Tablet

Tabros Pharma (Pvt) Ltd.

MRP: Rs. 1383.8220

We’d love to hear your thoughts!

Share your comment below and join the conversation ✨

Comments

No comments yet. Be the first!